2025 Medicare Prescription Drug Pricing 
Innovaare Compliance
JUNE 28, 2024
The upcoming Medicare Prescription Payment Plan (M3P), set to launch in January 2025, marks a significant shift in Medicare’s approach to prescription drug coverage. Price Transparency: Increased transparency in drug pricing to enable beneficiaries to make informed decisions.
Jane Sarashon
JULY 18, 2024
Following the BLS report on the CPI for June 2024, PwC published their new annual report from PwC titled Behind the Numbers 2025 tells us that commercial health care spending is expected to grow some 8.0% (Motor vehicle insurance costs grew a whopping 19.5% in the report, FYI). for Group plans and 7.5% and 7.0%, respectively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Innovaare Compliance
JUNE 27, 2024
The upcoming Medicare Prescription Payment Plan (M3P), set to launch in January 2025, marks a significant shift in Medicare’s approach to prescription drug coverage. Price Transparency: Increased transparency in drug pricing to enable beneficiaries to make informed decisions.
Healthcare Law Blog
FEBRUARY 22, 2023
The Rebate Programs are administered as part of the prescription drug affordability provisions of the Inflation Reduction Act (the “IRA”), which is aimed at “lower[ing] out-of-pocket drug costs for people with Medicare and improv[ing] the sustainability of the Medicare program for current and future generations.” [1]
Health Populi
APRIL 30, 2021
Spending on medicines, globally, will rebound this year and rise above pre-pandemic levels through 2025. Between 2021 and 2025, the annual growth global growth rate for prescription drugs spending is expected to range from 3% to 6%, a $1.6 As such, the debate on prescription drug pricing in the U.S.
Hall Render
MAY 10, 2024
Million CALIFORNIA California hospital dismisses CEO California physician pleads guilty to $2.5M million expansion ‘Very, very unusual.’ Million CALIFORNIA California hospital dismisses CEO California physician pleads guilty to $2.5M million expansion ‘Very, very unusual.’ million expansion ‘Very, very unusual.’
Hall Render
OCTOBER 4, 2024
NATIONAL 5 Stark law issues physicians are closely watching Anti-monopoly advocates urge FTC to block McKesson, Cardinal Health’s big-ticket oncology acquisitions Biden administration doles out $68.5M to resolve fraudulent lab testing allegations Lilly to invest another $4.5B to make breast cancer treatments safer St.
Expert insights. Personalized for you.
94 
Let's personalize your content